DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Comment by TrueNorth911on May 02, 2019 12:59am

58 Views

Post# 29698852

RE:RE:Where's RodSter2????

Yeah.... I could care less as well. Just like to bust his nuts.

News?... referring to the upcoming CKD Conference where DMAC is presenting?... Certainly can't hurt!

I'm more interested in getting some readouts from current phase of CKD... I wonder if they are through their co-hort of patients.... should be over by now?

Progess is slow, but believe they are progessing, as we haven't heard otherwise.

Bullboard Posts

Visionstate set to leverage success in the U.S. market